מזומנים למניה אחת Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics is implementing high-precision radiopharmaceuticals for the targeted destruction of tumors. Business growth is based on the expansion of clinical trials to capture the oncology segment. Currently, the R&D stage is characterized by a lack of profit and laboratory expenses. The estimated cash per share reflects liquidity dynamics, where the indicator value reaches 1.66, highlighting critical reserve points.
פילוחים אנליטיים של חברת Perspective Therapeutics

By focusing on the development of radiation therapy methods and delegating isotope production to external contractors, Perspective Therapeutics (CATX) requires stable capital to fund its outsourcing. The cash per share trend reflects the amount of net liquidity attributable to a single security, allowing investors to assess the business's financial stability and the risk of bankruptcy in the absence of operating profit.